Tag: application

MAHWAH, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Radware^® (NASDAQ: RDWR), a global leader in application security and delivery solutions for multi-cloud environments, today released its new report, 2025 Cyber Survey: Application Security at a Breaking Point. The survey reveals threat areas of rapidly growing concern as organizations’ cyber defenses lag well behind. This includes a major lack of protection against AI threats, as well as API and business logic attacks, among others.

RENO, Nev., June 12, 2025 (GLOBE NEWSWIRE) -- GreetEat Corporation (OTC: GEAT) is proud to announce that it has officially filed a patent application for its innovative core technology: “Video Conferencing with Food Delivery Vouchers.” The company is now patent pending, marking a major milestone in its mission to transform the way people meet, connect, and collaborate in virtual environments.

The "Automotive Operating System and AIOS Integration Research Report, 2025" explores AI's impact on automotive OS, highlighting trends in AI application. AIOS enhances vehicle OS with advanced intelligence, enabling seamless integration. The report outlines phases from AI application to AI-native systems, citing industry leaders like Geely, Huawei, and ThunderSoft.

JCDecaux SE
Société Européenne à Directoire et Conseil de Surveillance
Au capital de 3.264.372,84 €
Siège Social : 17, rue Soyer - 92200 Neuilly-sur-Seine (France)
307 570 747 RCS Nanterre

The global industrial robotics market is set to expand from USD 17.6 billion in 2025 to USD 39 billion by 2035, at a CAGR of 7.49%. Key segments include traditional and collaborative robots, with growth in payload and mobile robotics. Major players like ABB and FANUC lead in this evolving landscape.

On 5 June 2025, the Annual General Meeting of Arco Vara AS adopted the decision to issue a targeted share offering to specific investors in order to increase the company’s share capital.
Arco Vara AS announces that the targeted share issue approved by the shareholders has been successfully completed as of 11 June 2025 – the management board has adopted a resolution to shorten the subscription period due to early subscription of issued shares. In accordance with the adopted decision of the general meeting:

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor^® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil^® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD).